What Caused The Opening Gap In Aclaris Therapeutics?

Clinical-stage specialty pharmaceutical company Aclaris Therapeutics Inc ACRS had a large opening gap of -54.51%

Photo taken from the Opening Gap Signals tool inside Benzinga Pro.

Why Is It Moving?

Aclaris shares are trading lower after the company reported Phase 2 Trial results for ATI-502 did not meet its primary or secondary endpoints.

Photo taken from the ‘Why Is It Moving?’ Details tool inside Benzinga Pro.

For live updates on ACRS, log in or try Benzinga Pro today.